News – Page 1055 – Endpoints News

SIGN UP

Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII

8 years ago

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

8 years ago

Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetastatic prostate cancer

8 years ago

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

8 years ago

Allergan taps Catalent's Matthew Walsh as CFO; ReViral meets endpoints in PhIIa RSV trial

8 years ago

Stock plummets at EyeGate following Phase IIb flop for cataract surgery

8 years ago

As controversy over childhood deaths simmers in the Philippines, Sanofi balks at a Dengvaxia reimbursement

8 years ago

Skeptics pounce after Bristol-Myers scores an early hit on Opdivo-Yervoy combo for lung cancer

8 years ago

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

8 years ago

Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch

8 years ago

Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection

8 years ago

Buyout buzz hits fever pitch on report that Nektar is ‘exploring options’

8 years ago

Kenji Yasukawa takes the reins at Astellas; Voyager hunts for new CEO as Steven Paul goes back to research

8 years ago

Billion-dollar biosim maker mulls $500M Hong Kong IPO

8 years ago

Voyager co-founder Steven Paul steps down from CEO seat; Alnylam enters final stretch at the FDA with patisiran

8 years ago

RNA biotech Arcturus boots CEO Joseph Payne

8 years ago

Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on 'big things' in M&A — analyst

8 years ago

AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints

8 years ago

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Moderna boosts unicorn status with a whopping $500M raise and $7B valuation

8 years ago

UCB, investors back a neurosciences startup called Syndesi; Germany's Biofrontera increases US IPO pricing range

8 years ago

Think your odds of R&D success are miserable? MIT’s Andrew Lo might have a surprise for you

8 years ago

Nuclear scare to fuel anti-radiation drug sales? PTx buys ex-Sanofi drug just in case

8 years ago

Puma touts its latest advances in a basket trial for Nerlynx, as Europeans appear ready to reject the drug

8 years ago

First page Previous page 1052 1053 105410551056 1057 1058 Next page Last page